Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy The November 10, 2009, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results